45 results about "Targeted Radiotherapy" patented technology

The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high intensity focused ultrasound, cyberknife, hyperthermia, radiofrequency ablation, cryoablation, electrotome heating, hot water injection, alcohol injection, embolization, radiation exposure, photodynamic therapy, laser beam irradiation, and combinations thereof.

The invention provides a therapy method for glioblastoma multiforme (GBM). The therapy method uses a low-dose radiation to realize GBM tumor cell-targeted radiotherapy via sequentially administration of radiation enhancer-incorporated nanocarriers, 5-aminolevulinic acid, therapeutic ultrasound and therapeutic radiation.

The invention discloses a micromolecule lung cancer targeted radioactive therapeutic agent. Isotope 131I is marked with eight-peptide molecules with XGXG structures, wherein G shows L glycine, and X shows optional one of 20 amino acids. The invention further discloses a preparation method of the micromolecule lung cancer targeted radioactive therapeutic agent. The micromolecule lung cancer targeted radioactive therapeutic agent has good stability and biological distribution characteristics, can obviously suppress growth of tumour in a human lung cancer nude mouse animal model body, does not have obvious toxic and side effects to vitals such as livers, kidneys, lungs, hearts and the like, is applicable to targeted therapy for patients suffering from non-small cell lung cancer (squamous carcinoma and glandular cancer), and has an important clinical application value in the aspect of molecule targeted treatment for lung cancer.

The invention belongs to the technical field of binary targeted radiotherapy, in particular to a gamma spectrometer for boron neutron capture therapy irradiation beams, the spectrometer is used for measuring a BNCT irradiation beam, and comprises a gamma shielding cylinder (2) internally provided with a high-purity germanium semiconductor detector (1), a gamma shielding collimator (3) arranged inthe incident end of the gamma shielding cylinder (2), and a first neutron shielding layer (4) and a second neutron shielding layer (5) which are arranged outside the incident end of the gamma shielding cylinder (2), a BNCT irradiation beam sequentially passes through the first neutron shielding layer (4), the second neutron shielding layer (5) and the gamma shielding collimator (3) to irradiate the high-purity germanium semiconductor detector (1). The gamma energy spectrometer has the advantages of high energy resolution, small size, light weight and convenience in operation.

In particular, the present invention relates to a pharmaceutical composition containing a labeled complex Nu-BFC-A-(L) n-RGD polypeptide as defined in the present invention, an immunotherapeutic drug, and an optional nano antibody molecular imaging probe. The labeled complex provided by the invention is an effective targeted radiotherapy drug, can significantly increase infiltration of CD4 + and CD8 + T lymphocytes (rather than T-reg cells), and can significantly up-regulate PD-L1 expression on the surface of host myeloid immune cells (rather than tumor cells) in tumors. Therefore, the optimal synergistic effect can be obtained by carrying out PD-L1 blocking treatment after targeted radioactive drug delivery treatment. Besides, by applying the PD1 or PD-L1 nano antibody molecular imaging probe, the expression of PD-L1 in the tumor after targeted radiation treatment can be observed, and the method has guiding significance for making a treatment strategy of targeted radiation and immune combined treatment and is beneficial to improving the effect of the combined treatment.

The invention relates to a dose determination system, a dose determination method and a computer readable storage medium. The method comprises the following steps of: acquiring a target radiotherapy plan of an object, wherein the target radiotherapy plan comprises sub radiotherapy plans corresponding to a rack angle; based on the sub-radiotherapy plan corresponding to the rack angle, determining a target flux graph corresponding to the rack angle, wherein the target flux graph comprises a plurality of first sub-regions, and each first sub-region corresponds to a first weight value; based on the first weight value corresponding to each first sub-region, determining the number of sampling particles corresponding to each first sub-region; and determining target dose distribution of the object at the rack angle according to a Monte Carlo algorithm on the basis of the number of the sampling particles corresponding to each first sub-region.

Methods of protecting vascular integrity in a subject exposed to a targeted radiation therapy are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as TPOm, is used to protect vascular integrity following the radiation therapy.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenatedphospholipid ether has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-lifeof greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is -N+(CH3)3.

The invention discloses a clinical target region identification method and device applied to cervical cancer radiotherapy, and the method comprises the steps: obtaining a to-be-identified target image which is a 3D cervical cancer CT image; identifying the target image based on a target segmentation network model to obtain a segmentation result, the target segmentation network model being a neural network model generated by training based on a training sample corresponding to a 3D cervical cancer CT image, and the segmentation result being a to-be-determined radiotherapy clinical target region identified by the target segmentation network model; and based on the segmentation result, determining a cervical cancer target radiotherapy clinical target region. According to the invention, cervical cancer radiotherapy clinical target area sketching is realized based on the target segmentation network model, the efficiency and accuracy of cervical cancer radiotherapy clinical target area automatic sketching are improved, and the labor cost is reduced.

The invention provides a breast cancer lesion picture intelligent processing method, which comprises the following steps: marking existence state information of breast tissues on a breast region reference picture obtained by shooting a preset breast region of a target object for the first time to obtain a breast region reference picture; according to a preset time interval, continuously shooting a preset mammary gland region of the target object to obtain a plurality of mammary gland region tracking pictures, and marking existence state information of mammary gland tissues to obtain a mammary gland region diagnosis picture; and comparing all breast region diagnosis pictures with the breast region reference picture, determining existence state information of a breast cancer focus region, and obtaining breast cancer cell growth and diffusion judgment information, thereby adjusting operation parameters for performing radiotherapy treatment on the target object, and improving radiotherapy treatment efficiency. In this way, the data processing amount of picture analysis and recognition can be reduced, time progressive recognition and judgment can be carried out on the breast cancer lesion condition of the target object, and therefore targeted radiotherapy treatment can be carried out on breast cancer cells.

A radioactive or radioactivable nanostructure has a core, the core including at least two atoms, at least one of which being radioactive or radioactivable, and a shell encapsulating the core and selected among a selected material so that at the most, 20% of the radioactive radiation produced by the core are stopped or absorbed by the shell and the manufacturing method thereof.

The various uses of such a nanostructure, and more specifically the use thereof in the medical field, and more specifically in targeted radiotherapy are also disclosed.

The invention discloses an automatic sketching method and device for lumbosacral nerve roots and a storage medium, and relates to the stereotactic body radiotherapy technology, and the method comprises the steps: obtaining a plurality of belly and pelvic CT images, obtained in a CT examination mode, of target radiotherapy patients from a database, and taking the belly and pelvic CT images as first images; images with clear lumbosacral nerve root deformation of the multiple target radiotherapy patients obtained in other examination modes are obtained from the database and serve as second images; correcting the first image by using the second image to obtain a CT image with clear lumbosacral nerve root deformation, and taking the CT image as a third image; an abdominal and pelvic CT image, obtained in a CT examination mode, of the patient to be subjected to radiotherapy is obtained and serves as a fourth image; and processing the fourth image of the patient to be subjected to radiotherapy by using an automatic sketching model obtained by training the first image and the third image to obtain a sketched lumbosacral nerve root deformation CT image of the patient to be subjected to radiotherapy. According to the method, the defects that the consistency is poor and learning is difficult when the lumbosacral nerve root deformation is artificially sketched on the CT plain scanning image can be overcome, the nerve root deformation is clearer compared with that of CT imaging, and the price and the requirement are lower compared with that of MRI imaging.